Breast cancer is a neoplastic disease with very high incidence in women, with a current prediction that one of eight females will develop breast cancer during their lifespan and the trend appears grim. 1 Upto 30% of breast cancers can be characterized by high level expression of the receptor tyrosine kinase erbB2 (HER2), which seriously complicates the treatment of such neoplasias due to enhanced proliferative status and resistance to apoptosis. [2] [3] [4] The most frequently used therapeutics for HER2-positive breast cancer is the humanized antibody Herceptin (trastuzumab), often in combination with chemotherapeutic agents. 5 Although this approach has been applied with some success, Herceptin is a serious economical burden and, more importantly, exerts severe cardiotoxic side-effects. 6, 7 Mitocans, drugs with anti-cancer activity acting via mitochondrial destabilization, often causing early generation of reactive oxygen species (ROS), have been a recent focus of research. [8] [9] [10] We and others have been developing novel anticancer drugs from the group of vitamin E (VE), epitomized by the redox-silent a-tocopheryl succinate (a-TOS). [11] [12] [13] [14] [15] These agents have been shown to be efficient against a range of cancer types, 16 including HER2-positive breast tumors, as documented in studies with a-TOS and breast cancer cell lines with high level of HER2 as well as transgenic mice with spontaneous HER2-positive carcinomas. 17, 18 One problem with esters like a-TOS is that they are vulnerable to esterases, 19 making their stability/retention in the system relatively low, potentially jeopardizing their clinical application. This problem may be potentially overcome by using a recently synthesized analog of a-TOS, the ether a-tocopheryloxyacetic acid (a-TEA) that is resistant to esterase attack. 20 Encouragingly, the ether VE analog has been shown to suppress breast cancer in a syngeneic mouse model. 21, 22 In this communication, we document the effect of a-TEA on HER2-positive carcinomas using the transgenic FVB/ N   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57   58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114 c-neu mice, 23 and ascribe the superiority of a-TEA over a-TOS, in part, to its higher stability in vivo.
Material and Methods AQ4
Cell culture and reagents
The breast cancer cell line NeuTL was derived originally from breast carcinomas of the FVB/N c-neu transgenic mice 23 (see below). Human breast cancer cell line MDA-MB-453 (ATCC) and MCF7 HER2-18 cells 24 cells with high level of expression of HER2 were also used. The cells were grown in DMEM supplemented with 10% fetal bovine serum and antibiotics and were treated when $70% confluent. The cells were exposed to a-TOS (Sigma-Aldrich) or a-TEA 21 dissolved in EtOH. Control cells received identical volume of EtOH (<0.1%, v/v).
Assessment of apoptosis induction, proliferation rate, generation of reactive oxygen species and mitochondrial potential Apoptosis was quantified using the annexin V-FITC method, which detects phosphatidyl serine externalized in the early phases of apoptosis. Following exposure to various compounds, floating and attached cells were collected, washed with phosphate buffered saline (PBS), resuspended in 200 lL binding buffer, incubated for 20 min at 4 C with 2 lL annexin V-FITC plus 10 lL propidium iodide (PI) (10 lg/mL) and analyzed by flow cytometry (FACSCalibur) using channel 1 for annexin V-FITC binding and channel 2 for PI staining. 25 Proliferation was assessed using the standard MTT assay. Intracellular ROS levels were assessed using the fluorescent dye dihydroethidium. The cells were seeded in 24-well plates, treated, resuspended in PBS and supplemented with 5 lM DHEA, a cell-permeable, ROS-sensitive dye with relative specificity for superoxide. After a 30-min incubation in the dark, the cells were collected, washed and analyzed by flow cytometry. The level of ROS was expressed as mean fluorescence intensity. To assess the mitochondrial membrane potential (DW m,i ), we used the DW m,i -sensitive fluorescent probe tetramethylrhodamine methyl ester (Sigma) followed by flow cytometry assessment of red fluorescence of the mitochondria-accumulated probe.
Analysis of VE analogs
Serum samples were analyzed for VE analogs by highperformance liquid chromatography (HPLC). The system consisted of a Prostar 240 Solvent Delivery Module, Prostar 430 Autosampler and Prostar 335 Photodiode Array Detector (Varian). Samples for a-TEA and a-TOS analysis, spiked with the internal standard DL-a-tocopheryl acetate (a-TOA), were prepared by methanol precipitation and hexane extraction, respectively. An injection volume of 25 lL was used for each analysis. The stationary phase consisted of a Phenomenex Gemini C18 column (250 Â 4.6 mm, 5-lm particle size) with temperature at 30 6 1 C, the mobile phase consisted of acidified (0.25% v/v glacial acetic acid) methanol (A) and acetonitrile (B). Chromatographic separation of a-TEA and a-TOS from other VE analogs was achieved by linear gradient from 0-25% B and 0-31% B over 16 min, respectively. VE analogs were detected at the dual wavelength of 225 and 287 nm. Calibration curves (from 1.5 to 150 lM) were generated by least-squares quadratic curve-linear regression and had a correlation coefficient of !0.99.
Animal tumor experiments
The transgenic female FVB/N c-neu mice with spontaneous, HER2-positive ductal breast carcinomas in situ were used. 23 The animals present with tumors at 6-8, with 7 of 10 animals developing carcinomas. The animals with small tumors were subjected to therapy using a-TOS or a-TEA, both administered by intraperitoneal injection at 8.2 lmol per animal per dose (4.35 mg or 4 mg, respectively), with two doses given per week. The agents were dissolved in corn oil after presolubilization in EtOH (at 4% v/v). Control animals received corn oil/EtOH only. The appearance of tumors and their progression were visualized and quantified using the Vevo770 USI device equipped with the RMV708 scan-head (VisualSonics) operating at the frequency of 80 MHz and with the resolution of 30 lm.
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In vivo disposition studies
To assess the level of drugs in the mouse circulation, the animals were treated with a single dose of a-TEA or a-TOS at 8.2 lmol injected intraperitoneally exactly as for the tumor treatment experiments (see above) and blood taken from the tail vein at several subsequent time points. To assess hepatic processing of a-TEA and a-TOS, mice were injected with 8.2 lmol of the two agents and blood was collected from the animals after 24 hr by cannulating either the vena cava (systemic blood) or the hepatic vein (hepatic blood). The blood samples were analyzed for the levels of a-TOS, a-TEA or a-tocopherol (a-TOH) by HPLC (see above).
Assessment of lipid peroxidation in vivo
NeuTL cells (5 Â 10 6 ) were injected subcutaneously under the front arm to 3-month old FVB/N c-neu female mice. When solid tumors reached the size of $50 mm 3 (about 2 weeks), mice were injected intraperitoneally with either 100 lL solution of a-TOS (43.5 mg/mL) or a-TEA (40 mg/mL) every 3 days, while the control were injected with the same volume of the excipient. After 3 weeks of treatment, the mice were sacrificed and the tumor and liver tissue excised. The fresh tissue (25 mg) was placed in 250 lL RIPA buffer supplemented with protease inhibitors, sonicated for 15 s on ice, the samples centrifuged at 1,600g for 10 min at 4 C and the supernatant used for the lipid peroxidation evaluation using the TBARS Assay Kit (Cayman Chemicals). Briefly, 100 lL of the supernatant was supplemented with 100 lL SDS solution and 4 mL of the reagent, boiled for 1 hr and kept on ice for 10 min to stop the reaction. The samples were finally centrifuged at 1,600g for 10 min at 4 C and the absorbance 115  116  117  118  119  120  121  122  123  124  125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173   174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232 read at 540 nm. The lipid peroxide levels were calculated using the calibration curve and related to the protein concentration in the samples. The experiment was performed in triplicate.
VE analog stability analysis a-TEA or a-TOS (25 lM each) was incubated in freshly prepared human plasma (prepared by a standard procedure form blood obtained from healthy volunteers) at 37 C for 1, 2, 6, 12 and 24 hr, and the level of the VE analog assessed by HPLC as described above, with a-tocopheryl acetate as the internal control. Esterase activity of plasma samples was confirmed by adapted Ellman's method. 26 The experiment was performed in triplicate on two separate days.
Animal ethics
Animal studies were performed according to the guidelines of the Australian and New Zealand Council for the Care and Use of Animals in Research and Teaching and were approved by the local Animal Ethics Committee.
Statistical analysis
All data shown are mean values of three independent experiments (unless stated otherwise) 6 S.D. Statistical significance was assessed using Student's t-test and differences were considered significant at p < 0.05.
Results and Discussion
Ductal breast carcinomas with high expression of the oncogenic HER2 present a considerable problem in cancer management. 27 VE analogs epitomize an intriguing group of novel selective anti-cancer agents with promise to act across the landscape of solid tumors, most likely due to their effect on the mitochondria of cancer cells. 28 The remarkable efficacy of these agents stems from their effect on the mitochondrial redox chain, more specifically on complex II (CII). 29 We have shown that both a-TOS and a-TEA, 30, 31 as well as, more recently, mitochondrially targeted VE succinate, 32 act via CII and functional CII is required for their anti-cancer activity in vivo. 33 CII, now classified as a tumor suppressor, 34 is an excellent target for anti-cancer agents, since it only mutates in rare cancers, such as paragangliomas and phaeochromocytomas, while being intact in frequent cancers, with only one in one million breast cancer patients featuring mutated CII. 35, 36 The idea of this project was to document whether the esterase-stable a-TEA is more efficient in suppressing HER2-positive breast carcinomas than the prototypic VE analog a-TOS. We anticipated this to be the case since the ether form of the agent would be expected to be more stable (therefore exerting longer half-life) in the circulation of the experimental animal than the ester a-TOS, a paradigm documented earlier for another ether analog, a-tocopheryloxybutyric acid. 37 Further, we showed before that a-TOS efficiently kills cultured HER2-positive breast cancer cells by causing mitochondria-dependent apoptosis. 17 We first assessed the effect of a-TOS and a-TEA on several cell lines with high level of HER2, i.e., the human lines MCF7 HER2-18 and MDA-MB-453, and the NeuTL murine breast cancer cells, originally derived from spontaneous breast carcinomas of the transgenic FVB/N c-neu mice. We tested the two VE analogs for their efficacy in the inhibition of the cellular viability, induction of apoptosis, generation of ROS and the level of dissipation of the mitochondrial potential. Figure  F1  1 reveals that the effect of a-TOS and a-TEA was similar for all three cell lines. Although the ether analog was slightly more efficient, it did not reach statistically significant difference compared to the effect of a-TOS. Similarly, we found slightly while not significantly increased apoptosis in the three HER2-positive breast carcinoma cell lines induced by a-TEA compared to a-TOS (Fig.  F2  2) . Finally, since a-TOS and a-TEA act by targeting the mitochondrial CII, we tested the two drugs for their ability to cause ROS generation in the three cell lines as well as their propensity to cause dissipation of DW m,i. . Again, we observed the same trend in the activities of a-TEA and a-TOS with no significant difference (Fig.  F3  3) . The relatively small variation in the effect of a-TOS and a-TEA in vitro can be ascribed to the fact that cancer cells possess low levels of esterases. In support of this premise, we 233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291   292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348 observed virtually no hydrolysis of a-TOS in different cancer cell lines. 38 We next evaluated the effect of a-TOS and a-TEA on the progression of HER2-positive tumors using the transgenic FVB/N c-neu mice. 23 This is an excellent model for testing the efficacy of prospective drugs against breast cancer, since the transgenic animals develop spontaneous breast carcinomas within the context of an intact immune system. Moreover, being morphologically ductal in situ tumors, they represent one of the most frequent types of breast carcinomas found in human patients. Further, this is an ideal experimental tumor model, since it allows for testing potential anticancer agents for their propensity to suppress breast tumors with high level expression of the oncogene HER2. Administration of the VE analogs in FVB/N c-neu mice commenced immediately after tumors were detected by ultrasound imaging (USI), at their size of $50 mm 3 . We administered both drugs intraperitoneally in corn oil, following their presolubilization in a small volume of EtOH. Although a-TEA can be given orally since it is resistant to esterases and, unlike a-TOS, will not be hydrolyzed upon uptake by the colon epithelial cells, 21, 22 we administered it intraperitoneally to compare its effects with those of a-TOS that is subject to esterase hydrolysis. 19 Figure  F4  4 clearly documents that a-TEA was significantly more efficient in suppression of breast carcinomas in the transgenic animals compared to a-TOS. Importantly, even during this relatively short experiment, we observed tumor disappearance in 20% (2 of 10) of the animals treated with a-TEA, which did not occur when the animals were treated with its ester counterpart.
Cancer Cell Biology
Since VE analogs induce ROS in HER2-high cell lines (c.f. Fig. 3 ), we tested whether this translates to lipid generation also in vivo. To do this, we exposed mice with NeuTL cell-351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406  407  408  409   410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467 468 S.E.M., derived from at least six animals in each group, the data in panel c are mean values 6 S.D. (n ¼ 3). The symbol ''*'' denotes statistically significant differences between the control mice and the treated mice, the symbol ''**'' indicates statistically significant differences between mice treated with a-TEA and a-TOS, with p < 0.05 in both cases. derived xenografts with a-TOS and a-TEA and tested the tumor and liver tissue for lipid peroxidation using a TBARS assay (see Material and Methods). Figure 4c documents that there was no difference in the level of lipid peroxides in the tissue from control and treated mice. This indicates that the levels of ROS that are needed to induce apoptosis in cancer cells are relatively low and that they can be considered signaling molecules that trigger apoptosis rather than oxidizing tissue biomolecules in random manner. This is consistent with our findings that VE analogs cause generation of ROS by targeting the ubiquinone-binding site of CII, [31] [32] [33] [34] which then trigger Mst1/FoxO1-dependent transcription of the Noxa protein 33, 39, 40 with ensuing generation of the mitochondrial Bak channel and cytosolic translocation of cytochrome. 40, 41 We then tested the hypothesis that a-TEA is more efficient in tumor suppression than a-TOS due to its better in vivo stability by studying pharmacokinetics of the two compounds. To do this, we injected a cohort of FVB/N c-neu animals with a single dose (4.35 or 4 mg/mouse) of a-TOS or a-TEA at a level similar to that used in the cancer treatment experiments above. After this, blood was taken from the tail vein of the mice on days 1, 3, 7, 9 and 11 post-drug administration and the plasma analyzed, as relevant, for the levels of a-TOS, a-TEA and a-TOH. As documented in Figures  F5 5a and 5b, a-TEA was more stable in the system than a-TOS, i.e., the FVB/N c-neu mice exerted faster disposition of a-TOS than of its ether counterpart. More specifically, there was a rapid decline of a-TOS in the mouse circulation by Day 4, while there was little change in the level of a-TEA, and on Day 9, when there was still $30% of the original level of a-TEA in the blood, a-TOS was barely detectable. Importantly, the longer half-life of a-TEA in the circulation of the experimental mice was not accompanied by an adverse reaction of the animals, as judged from no change in their behavioral pattern.
We previously observed that a-TOS, a compound that is unstable in the presence of esterases, 42 is cleaved in the liver of mice. This could explain the faster disappearance of a-TOS from the circulation of mice compared to its ether counterpart. To test this possibility, we injected FVB/N c-neu mice with a single dose of a-TEA or a-TOS and analyzed their levels plus the level of a-TOH in systemic and hepatic blood. We collected blood by cannulating the vena cava and the hepatic vein, making sure that the hepatic blood did not mix with systemic blood. Figures 5c and 5d shows that the level of a-TEA was comparable in the systemic and hepatic blood, while the level of a-TOS was 3-4 times lower in the hepatic blood when compared to the generic blood. This suggests that a-TOS is hydrolyzed in the liver and only a fraction of the total pool of the drug is returned into circulation. On the other hand, a-TEA, which cannot be hydrolyzed, is efficiently recycled, so that its half-life in the blood plasma is longer. Rather surprisingly, the level of a-TOH in both the systemic and hepatic blood in the a-TOS-injected animals was found to be about half of that in the a-TEA-injected animals. We would expect the opposite due to hydrolysis of a-TOS to a-TOH. It is possible, although, that under this setting, a-TOS is hydrolyzed to a-TOH and/or processed to other metabolites of the compound, 43, 44 or that in the presence of a-TEA, a-TOH is retained more efficiently. Notwithstanding, the lower level of a-TOS in the hepatic blood explains its lower half-life in the circulation of the animals, a reason behind its shorter half-life in vivo compared   469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527   528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586 Cancer Cell Biology The symbol ''*'' in panels a and b denotes statistically significant differences between levels of a-TEA (a) and a-TOS (b), with p < 0.05, the symbol ''*'' in panel d indicates statistically significant differences between levels of a-TOS in the systemic and hepatic blood, with p < 0.05.
to a-TEA, which is more efficient in suppression of the HER2-positive breast carcinomas.
Since it is possible that the VE analogs may be also hydrolyzed, at least to some extent, by components of blood plasma, we tested their stability by incubating in freshly prepared plasma for time points up to 24 hr. The results in Figure 5e document that while we observed a drop of a-TOS from the original 25 lM to 12-13 lM within 24 hr, a-TEA was much more stable with the drop from 25 lM to only $20 lM. This corroborates the above data showing much higher stability of a-TEA compared to its ester analog.
It was reported earlier for an ovarian cancer cell line that a-TEA induces more apoptosis than a-TOS due to esterasemediated hydrolysis of the latter by the cells. 45 To resolve this issue here, we tested the stability of a-TOS and a-TEA in NeuTL cells. In brief, the cells were incubated for 2 hr with 50 lM a-TOS or a-TEA, washed and incubated in fresh medium without the VE analogs. Figure 5f documents that there was <10% loss of the agents within 24 hr, which documents that the cells do not hydrolyze a-TOS, a finding consistent wits our earlier report showing high stability of a-TOS in mesothelioma cells. 38 One potential problem with increased levels of a-TOH may be its interference with the proapoptotic activity of VE analogs like a-TOS.
11 However, to jeopardize the toxicity of the proapoptotic agents, the level of the redox-active a-TOH needs to be similar to that of its apoptogenic counterparts.
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This is not the case in vivo, since the levels of a-TOH are 5-10-fold lower than that of a-TOS or a-TEA (c.f. Ref. 46 and Fig. 5 in this article) .
We conclude that the ether analog of VE, a-TEA, is more efficient than a-TOS in suppression of breast carcinomas in a mouse model of breast tumors over-expressing the receptor tyrosine kinase erbB2 (HER2), due to its greater stability in the experimental animals. This report justifies further testing of a-TEA as an efficient drug against HER2-positive breast carcinomas. We propose that VE analogs, such as a-TEA, may become in the future an alternative for Herceptin, exerting considerable cardiotoxicity, 6, 7 in the treatment of HER2-positive breast cancer patients.
